/

QNRX

Quoin Pharmaceuticals, Ltd.Closed

4.15−0.21 −4.82%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

4.49

Prev close

4.36

Day range

4.154.56

52-week range

3.2523.50

Volume

26.33K0.05×

Mkt cap

19.94M

P/E ttm

—

Fwd P/E

-1.30

EPS ttm

-5.67

Div yield

0.00%

Earnings

—

From 52w high

−82.34%

Price Chart

Yahoo Finance · delayed

QNRXOct 13, 2026O 4.49H 4.56L 4.15C 4.15−0.21 (−4.82%)Vol 26.40K

SMA 505.68
SMA 2006.64

1Y change −79.76% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

QNRX Quoin Pharmaceuticals, Ltd. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −12.08%
1 month: −38.88%
3 months: −4.60%
6 months: −34.13%
Year to date: −71.24%
1 year: −72.07%

Valuation & ownership

Market cap: 19.94M
Enterprise value: −441.41K
P/E (ttm): —
Forward P/E: -1.30
PEG ratio: —
Price / book: 2.12
Price / sales (ttm): —
EV / EBITDA: 0.02
EPS (ttm): -5.67
EPS (forward): -3.19
Beta (5y monthly): 1.75
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 4.80M
Float: 1.93M
Short % of float: 1.36%
Short ratio (days): 0.54
Held by insiders: 3.67%
Held by institutions: 27.81%
Avg volume (3m): 549.97K
50-day average: 5.69
200-day average: 6.69
52-week change: −72.07%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 29.1
vs 50-day SMA: −26.98%
vs 200-day SMA: −37.54%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 13.56%
Realised vol (20d, ann.): 85.2%
From 52-week high: −82.34%
From 52-week low: +27.69%

ANR

Analyst Consensus

7 analysts

Consensus

Strong buy

1.17 on a 1 (strong buy) – 5 (sell) scale

Mean target

20.71

+399.14% implied

Low 12.00Median 20.00High 35.00

Recommendation trend

Now6 / 0 / 0
1m ago5 / 0 / 0

DES

About Quoin Pharmaceuticals, Ltd.

Yahoo Finance profile

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.

Sector: Healthcare
Industry: Biotechnology
Employees: 4
Headquarters: Ashburn, VA, United States
Website: quoinpharma.com
Officers: Dr. Michael Myers Ph.D. Co-Founder, CEO & Chairman
Ms. Denise Carter Co-Founder, COO & Director
Ms. Sally Lawlor Chief Financial Officer

SEAS

Seasonality · QNRX

2016–2026 · monthly returns

Strongest month Oct +4.65%Weakest month Dec −15.62%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-50.0	16.0	-21.1	-1.8	-21.9	-4.3	-8.1	39.8	-26.7	-9.0			−71.2%
2025	-48.8	-6.6	-28.0	-13.7	26.0	8.2	-27.4	10.1	-2.5	57.2	92.5	-33.7	−36.7%
2024	-27.2	-23.0	-65.5	-25.5	9.7	-25.4	3.4	4.3	-21.2	51.5	-19.7	8.5	−86.7%
2023	17.6	-65.9	-16.5	5.0	-14.8	17.4	31.2	-26.9	-27.8	-1.9	22.2	-1.4	−71.2%
2022	-23.6	-20.1	19.8	-39.8	-20.7	-29.1	-20.7	-26.7	-31.8	-17.0	-9.7	-15.0	−93.8%
2021	33.3	16.0	-6.0	-19.7	24.2	19.8	13.9	24.1	-12.9	-36.9	-67.4	-52.0	−78.9%
2020	2.3	-7.5	-30.0	68.0	19.0	7.1	0.0	-31.7	-2.3	-13.8	12.2	6.4	−2.7%
2019	13.7	-56.0	-3.7	-14.4	-19.1	-27.1	17.6	-21.5	3.6	7.0	-3.1	-12.3	−78.9%
2018	20.0	-14.2	-11.5	2.2	13.5	-3.4	-12.9	-10.9	-14.2	-7.6	-24.1	-37.1	−70.0%
2017	0.2	112.8	30.5	7.7	-1.4	-11.7	-7.9	18.3	-9.5	17.0	-10.1	-16.3	+126.5%
2016									2.9	-8.9	-23.6	-3.4	−30.9%

INSD

Insider Activity · QNRX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 30, 2026	Culverwell Anthony JamesDirector	Purchase at price 6.22 per share.	6.1K	$38.23K
Aug 30, 2026	Carter Denise PChief Operating Officer	Purchase at price 6.22 per share.	20.5K	$127.45K
Aug 30, 2026	Myers MichaelChief Executive Officer	Purchase at price 6.22 per share.	20.5K	$127.45K
Aug 30, 2026	Lawlor Sally BridgetChief Financial Officer	Purchase at price 6.22 per share.	10.2K	$63.72K
Aug 26, 2026	Langer Dennis HDirector	Stock Award(Grant) at price 5.15 per share.	34.5K	$177.85K
Aug 26, 2026	Culverwell Anthony JamesDirector	Stock Award(Grant) at price 5.15 per share.	31.4K	$161.46K
Oct 13, 2025	Langer Dennis HDirector	Purchase at price 14.05 per share.	15.2K	$212.89K
Dec 22, 2024	Carter Denise PChief Operating Officer	Purchase at price 0.45 per share.	555.6K	$250.00K
Dec 22, 2024	Dunn GordonChief Financial Officer	Purchase at price 0.45 per share.	122.2K	$55.00K

QNRX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

QNRX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Quoin Pharmaceuticals, Ltd.

Seasonality · QNRX

Insider Activity · QNRX

Congress Trades · QNRX

Investors Holding QNRX

Investors Holding QNRX

Congress Trades · QNRX

Insider Activity · QNRX

Seasonality · QNRX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Quoin Pharmaceuticals, Ltd.

Financial Snapshot

Earnings & Dividends

News